Please ensure Javascript is enabled for purposes of website accessibility

Why Ocugen and Nikola Are Powering the Nasdaq Higher

By Dan Caplinger - Updated Apr 22, 2021 at 12:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Favorable news from two key sectors helped support the broader market.

The Nasdaq Composite (^IXIC 0.00%) climbed back above the 14,000 level early Thursday afternoon, rising nearly half a percent on the day as of 1 p.m. EDT. Investors were more excited about the Nasdaq's prospects than the rest of the stock market, as most other large-cap major market benchmarks were flat to lower on the day.

Lately, the biotech and electric vehicle industries have been important drivers of growth for the stock market generally and the Nasdaq in particular. Thursday's sizable gains from Ocugen (OCGN 7.44%) and Nikola (NKLA 9.96%) showed that those two powerful trends can still pack a punch when it comes to lifting the overall market. Below, we'll discuss why these two stocks were doing so well today.

Ocugen keeps climbing on good vaccine news

Shares of Ocugen jumped 17% early Thursday afternoon. The biotech company has been working closely with a developer of a coronavirus vaccine candidate in India, and the latest news from its clinical trials has made investors more upbeat about the immediate prospects for the vaccine.

Ocugen shares began rising on Wednesday after the company's India-based partner, Bharat Biotech, released the latest data from its phase 3 trial of its Covaxin candidate vaccine. The two-dose trial showed 78% efficacy in preventing COVID-19 infection, with 70% efficacy against asymptomatic COVID-19 infections. Covaxin has done even better in preventing severe cases requiring hospitalization.

India is going through a massive spike in COVID-19 cases, so the news is extremely encouraging for Bharat. For Ocugen, however, the key is making Covaxin available in the U.S. market, as its partnership with Bharat covers U.S. sales of the vaccine.

Investors are hopeful that the data could support Emergency Use Authorization from the Food and Drug Administration quickly enough for Ocugen to see demand for Covaxin. As vaccination efforts progress, however, the window for maximum profit potential could close for both Bharat and Ocugen.

Nikola makes a deal

Elsewhere, shares of Nikola were up 19%. The electric truck company is moving forward with a key element of its strategic plan, and investors are pleased to see some positive news after a long period of dealing with controversy.

Black Nikola truck on a bridge.

A Nikola semi. Image source: Nikola.

Nikola announced an agreement with TravelCenters of America (TA 3.80%) to provide for the installation of hydrogen fueling stations for heavy-duty trucks. The companies will collaborate initially on two installations at existing TravelCenter-Petro stations in California, with the goal of having them ready for commercial operation by the first quarter of 2023.

Nikola hopes that putting hydrogen infrastructure in place at key locations in the U.S. will help accelerate adoption of hydrogen fuel-cell technology, including its own Nikola Tre fuel-cell electric vehicle. The two locations will specifically allow for zero-emission commercial vehicle transport in and around Los Angeles and into the Central Valley region of California.

To succeed, Nikola will have to work on multiple fronts simultaneously, not only making sure that the infrastructure is in place to support its fleet of vehicles but also moving forward with design, development, and production of those vehicles. It's that second part of the strategy that has some investors still nervous about Nikola's long-term prospects, and that's why even after today's gains, the stock is down more than 80% from its highs last summer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
OCGN
$2.60 (7.44%) $0.18
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
^IXIC
$11,127.85 (0.00%) $0.00
TravelCenters of America Inc. Stock Quote
TravelCenters of America Inc.
TA
$36.32 (3.80%) $1.33
Nikola Corporation Stock Quote
Nikola Corporation
NKLA
$5.19 (9.96%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.